Date: 2021-09-08
Your Name:Qitong Zheng
Manuscript Title: Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cance
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None The project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-I2M-5-035).	
2	Grants or contracts from	Time frame: past $\sqrt{}$ None	36 months

	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	√ None	
	noyantes of nechises	vnone	
4	Consulting fees	√_None	
5	Payment or honoraria for	√ None	
5	lectures, presentations,	vNone	
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	a) None	
6	testimony	√None	
	,		
7	Support for attending	√None	
	meetings and/or travel		
8	Patents planned, issued or	√ None	
8	pending	_ vNone	
9	Participation on a Data	√None	
	Safety Monitoring Board or		
10	Advisory Board  Leadership or fiduciary role	√ None	
10	in other board, society,	vNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	\None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	√ None	
13	financial interests		

The author reports that the project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-12M-5-035).

Please place an "X" next to the following statement to indicate your agreement:		
_X I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:2021-09-08
Your Name:Chen Wu
Manuscript Title: Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cance
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None The project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-I2M-5-035).	
2	Grants or contracts from	Time frame: past $\sqrt{}$ None	36 months

	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	√ None	
	noyantes of nechises	vnone	
4	Consulting fees	√_None	
5	Payment or honoraria for	√ None	
5	lectures, presentations,	vNone	
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	a) None	
6	testimony	√None	
	,		
7	Support for attending	√None	
	meetings and/or travel		
8	Patents planned, issued or	√ None	
8	pending	_ vNone	
9	Participation on a Data	√None	
	Safety Monitoring Board or		
10	Advisory Board  Leadership or fiduciary role	√ None	
10	in other board, society,	vNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	\None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	√ None	
13	financial interests		

The author reports that the project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-12M-5-035).

Please place an "X" next to the following statement to indicate your agreement:		
_X I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: 2021-09-08
Your Name:Huangshu Ye
Manuscript Title: Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cance
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None The project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-I2M-5-035).	
2	Grants or contracts from	Time frame: past $\sqrt{}$ None	36 months

	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	√ None	
	noyantes of nechises	vnone	
4	Consulting fees	√_None	
5	Payment or honoraria for	√ None	
5	lectures, presentations,	vNone	
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	a) None	
6	testimony	√None	
	,		
7	Support for attending	√None	
	meetings and/or travel		
8	Patents planned, issued or	√ None	
8	pending	_ vNone	
9	Participation on a Data	√None	
	Safety Monitoring Board or		
10	Advisory Board  Leadership or fiduciary role	√ None	
10	in other board, society,	vNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	\None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	√ None	
13	financial interests		

The author reports that the project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-
I2M-5-035).

Please place an "X" next to the following statement to indicate your agreement:
_X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 2021-09-08	
Your Name:Zhenggang Xu	
Manuscript Title: Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cand	er
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None The project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-I2M-5-035).	
2	Grants or contracts from	Time frame: past $\sqrt{}$ None	36 months

	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	√ None	
	noyantes of nechises	vnone	
4	Consulting fees	√_None	
5	Payment or honoraria for	√ None	
5	lectures, presentations,	vNone	
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	a) None	
6	testimony	√None	
	,		
7	Support for attending	√None	
	meetings and/or travel		
8	Patents planned, issued or	√ None	
8	pending	_ vNone	
9	Participation on a Data	√None	
	Safety Monitoring Board or		
10	Advisory Board  Leadership or fiduciary role	√ None	
10	in other board, society,	vNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	\None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	√ None	
13	financial interests		

The author reports that the project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-
I2M-5-035).

Please place an "X" next to the following statement to indicate your agreement:
_X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:2021-09-08
Your Name:Yang Ji
Manuscript Title: Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cance
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None The project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-I2M-5-035).	
2	Grants or contracts from	Time frame: past $\sqrt{}$ None	36 months

	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	√ None	
	noyantes of nechises	vnone	
4	Consulting fees	√_None	
5	Payment or honoraria for	√ None	
5	lectures, presentations,	vNone	
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	a) None	
6	testimony	√None	
	,		
7	Support for attending	√None	
	meetings and/or travel		
8	Patents planned, issued or	√ None	
8	pending	_ vNone	
9	Participation on a Data	√None	
	Safety Monitoring Board or		
10	Advisory Board  Leadership or fiduciary role	√ None	
10	in other board, society,	vNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	\None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	√ None	
13	financial interests		

The author reports that the project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-
I2M-5-035).

Please place an "X" next to the following statement to indicate your agreement:					
_X I certify that I have answered every question and have not altered the wording of any of the questions on thi form.					

Date:2021-09-08
Your Name:Jianhua Rao
Manuscript Title: Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cance
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None The project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-I2M-5-035).	
2	Grants or contracts from	Time frame: past $\sqrt{}$ None	36 months

	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	√_None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	VNone	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	VNone	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	VNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

The author reports that the project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-I2M-5-035).

Please place an "X" next to the following statement to indicate your agreement:

_X I certify that I have answer form.	ed every question and have not	altered the wording of any of t	he questions on this

Date: 2021-09-08	
Your Name:Ling	; Lu
Manuscript Title:	_ Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer
Manuscript number	(if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,	The project was supported	
	provision of study materials,	by the National Natural	
	medical writing, article	Science Foundation of	
	processing charges, etc.)	China (81871259 and	
	No time limit for this item.	820706752), and the	
		Chinese Academy of	
		Medical Sciences	
		Innovation Fund for	
		Medical Sciences (No.	
		2019-I2M-5-035).	
	ı	Time frame: past	36 months
2	Grants or contracts from	√_None	

	any entity (if not indicated in item #1 above).		
3	Royalties or licenses		
4	Consulting fees	√_None	
_			
5	Payment or honoraria for lectures, presentations,	√None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
7	Support for attending meetings and/or travel	√None	
	meetings and/or traver		
8	Patents planned, issued or	None	
	pending		
•			
9	Participation on a Data	√None	
	Safety Monitoring Board or		
10	Safety Monitoring Board or Advisory Board	√ None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role		
10	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy	None	
	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		
10	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy		
	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		
11	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options		
	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment,		
11	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical		
11	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment,		
11	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-		
11	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services		
11	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-		

The author reports that the project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-12M-5-035).
12IVI-5-U35).

Please place an "X" next to the following statement to indicate your agreement:					
_X I certify that I have answered every question and have not altered the wording of any of the questions on thi form.					

Date: 2021-09-08
Your Name:Yaqing Zhu
Manuscript Title: Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancel
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,	The project was supported	
	provision of study materials,	by the National Natural	
	medical writing, article	Science Foundation of	
	processing charges, etc.)	China (81871259 and	
	No time limit for this item.	820706752), and the	
		Chinese Academy of	
		Medical Sciences	
		Innovation Fund for	
		Medical Sciences (No.	
		2019-I2M-5-035).	
	ı	Time frame: past	36 months
2	Grants or contracts from	√_None	

any entity (if not indicated in item #1 above).  Royalties or licenses	
3 Royalties or licenses	
4 Consulting fees	
Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Patricipation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role  None None None None	
Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Patricipation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role  None None None None	
lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role    None	
lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role    None	
lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role    None	
speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role    None	
manuscript writing or educational events  6  Payment for expert testimony  7  Support for attending meetings and/or travel  8  Patents planned, issued or pending  9  Participation on a Data Safety Monitoring Board or Advisory Board  10  Leadership or fiduciary role    None	
6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role	
testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role  - √_None  - √_None  - √_None	
7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role	
meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role  Safety Monitoring Leadership or fiduciary role	
meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role  Safety Monitoring Leadership or fiduciary role	
8 Patents planned, issued or pending	
pending  9 Participation on a DataNone Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary roleNone	
pending  9 Participation on a DataNone Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary roleNone	
pending  9 Participation on a DataNone Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary roleNone	
9 Participation on a Data√None Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role√None	
Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role√_None	
Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role√_None	
Advisory Board  10 Leadership or fiduciary role√_None	
10 Leadership or fiduciary roleNone	
in other hoard society	
committee or advocacy	
group, paid or unpaid  11 Stock or stock options √ None	
12 Receipt of equipment,√None	
materials, drugs, medical	
writing, gifts or other services	
13   Other financial or non-   V None	
13 Other financial or non- financial interests $\_\sqrt{\_None}$	

The author reports that the project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-
I2M-5-035).

Please place an "X" next to the following statement to indicate your agreement:
_X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 2021-09-08
Your Name:Feng Cheng
Manuscript Title: Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cance
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None The project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-I2M-5-035).	
2	Grants or contracts from	Time frame: past √ None	36 months

	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√_None	
_			
5	Payment or honoraria for lectures, presentations,	√None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
7	Support for attending meetings and/or travel	√None	
	meetings and/or traver		
8	Patents planned, issued or	√None	
	pending		
•			
9	Participation on a Data	√None	
	Safaty Manitoring Board or		
	Safety Monitoring Board or Advisory Board		
10	Advisory Board	√ None	
10			
10	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy	None	
	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		
10	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy		
	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		
11	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options		
	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment,		
11	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical		
11	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment,		
11	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-		
11	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services		
11	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-		

The author reports that the project was supported by the National Natural Science Foundation of China (81871259 and 820706752), and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-12M-5-035).
12IVI-5-U35 <i>)</i> .

Please place an "X" next to the following statement to indicate your agreement:
_X I certify that I have answered every question and have not altered the wording of any of the questions on this form.